Q3 EPS Estimates for DENTSPLY SIRONA Cut by William Blair

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Stock analysts at William Blair cut their Q3 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a research report issued to clients and investors on Thursday, May 8th. William Blair analyst B. Vazquez now expects that the medical instruments supplier will post earnings of $0.49 per share for the quarter, down from their previous estimate of $0.51. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. William Blair also issued estimates for DENTSPLY SIRONA’s Q3 2026 earnings at $0.53 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The firm had revenue of $879.00 million during the quarter, compared to the consensus estimate of $854.75 million. During the same quarter in the previous year, the company posted $0.42 EPS. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year.

A number of other research firms also recently weighed in on XRAY. Jefferies Financial Group downgraded DENTSPLY SIRONA from a “buy” rating to a “hold” rating and dropped their target price for the stock from $30.00 to $20.00 in a research report on Thursday, January 23rd. Piper Sandler dropped their target price on DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. StockNews.com upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Friday. Wells Fargo & Company dropped their target price on DENTSPLY SIRONA from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, February 28th. Finally, Mizuho dropped their target price on DENTSPLY SIRONA from $21.00 to $18.00 and set a “neutral” rating for the company in a research report on Thursday, March 13th. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.27.

DENTSPLY SIRONA Trading Down 0.6%

XRAY stock opened at $15.81 on Monday. The company has a market cap of $3.15 billion, a P/E ratio of -7.64, a PEG ratio of 1.80 and a beta of 0.92. DENTSPLY SIRONA has a twelve month low of $12.16 and a twelve month high of $28.69. The company has a quick ratio of 0.84, a current ratio of 1.25 and a debt-to-equity ratio of 0.72. The business has a fifty day moving average of $14.36 and a 200-day moving average of $17.54.

DENTSPLY SIRONA Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, March 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.05%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -14.10%.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 15,142 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was purchased at an average cost of $16.51 per share, with a total value of $249,994.42. Following the completion of the purchase, the director now owns 81,971 shares in the company, valued at approximately $1,353,341.21. The trade was a 22.66% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XRAY. Barclays PLC grew its stake in DENTSPLY SIRONA by 21.8% in the third quarter. Barclays PLC now owns 306,809 shares of the medical instruments supplier’s stock valued at $8,301,000 after acquiring an additional 54,920 shares during the period. Pallas Capital Advisors LLC acquired a new position in DENTSPLY SIRONA in the fourth quarter valued at about $264,000. Oak Thistle LLC grew its stake in DENTSPLY SIRONA by 93.2% in the fourth quarter. Oak Thistle LLC now owns 31,590 shares of the medical instruments supplier’s stock valued at $600,000 after acquiring an additional 15,240 shares during the period. First Community Trust NA acquired a new position in DENTSPLY SIRONA in the fourth quarter valued at about $163,000. Finally, UMB Bank n.a. grew its stake in DENTSPLY SIRONA by 60.8% in the fourth quarter. UMB Bank n.a. now owns 1,492 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 564 shares during the period. 95.70% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.